P-110 Ixazomib maintenance in transplant-ineligible patients with newly diagnosed multiple myeloma: final overall survival analysis from the TOURMALINE-MM4 study — Meletios A Dimopoulos (2023) | RDL Network
P-110 Ixazomib maintenance in transplant-ineligible patients with newly diagnosed multiple myeloma: final overall survival analysis from the TOURMALINE-MM4 study
Meletios A Dimopoulos, Ivan Špıčka, Hang Quach, Albert Oriol, Roman Hájek, Mamta Garg, Meral Beksaç, Sara Bringhen, Eirini Katodritou, Wee Joo Chng, Xavier Leleu, Shinsuke Iida, María‐Victoria Mateos, Gareth J. Morgan, Alexander Vorog, Richard Labotka, Bingxia Wang, Antonio Palumbo, Sagar Lonial
Sara Bringhen, Luděk Pour, Reuben Benjamin, Sebastian Grosicki, Chang‐Ki Min, Danielle Leão Cordeiro de Farias, Alexander Vorog, Richard Labotka, Bingxia Wang, Dasha Cherepanov, Lauren E. Cain, Sudhakar Manne, S. Vincent Rajkumar, Meletios A Dimopoulos
Fredrik Schjesvold, Hartmut Goldschmidt, Vladimír Maisnar, Ivan Špıčka, Neils Abildgaard, Philip Rowlings, Lauren E. Cain, Dorothy Romanus, Kaveri Suryanarayan, S. Vincent Rajkumar, Dawn Odom, Ari Gnanasakthy, Meletios A Dimopoulos
Meletios A Dimopoulos, Sebastian Grosicki, W Wiktor-Jędrzejczak, Hareth Nahi, Astrid Gruber, Markus Hansson, Neeraj Gupta, Catriona Byrne, Richard Labotka, Zhaoyang Teng, Huyuan Yang, Norbert Grząśko, Shaji Kumar
Discussion(0)
No comments yet. Be the first to comment.